Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;8(5):715-722.
doi: 10.21037/tlcr.2019.05.12.

Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

Andrew J Piper  1 , Kartik Sehgal  1 , Daniel B Costa  1 , Deepa Rangachari  1
Affiliations
Editorial

Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

Andrew J Piper et al. Transl Lung Cancer Res. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: D Rangachari reports non-financial support (institutional research support) from Bristol-Myers Squibb, Novocure, and Abbvie/Stemcentrx; all outside the submitted work. DB Costa reports personal fees (consulting fees and honoraria) and non-financial support (institutional research support) from Takeda/Millennium Pharmaceuticals, personal fees (consulting fees) and non-financial support (institutional research support) from AstraZeneca, personal fees (honoraria) and non-financial support (institutional research support) from Pfizer, non-financial support (institutional research support) from Merck Sharp & Dohme Corporation, non-financial support (institutional research support) from Merrimack Pharmaceuticals, non-financial support (institutional research support) from Bristol-Myers Squibb, non-financial support (institutional research support) from Clovis Oncology, non-financial support (institutional research support) from Tesaro; all outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Approach to selection of first line therapy options in advanced/metastatic NSCLC. NSCLC, non-small cell lung cancer; TMB, tumor mutational burden. mut. = mutation.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54. 10.1038/nature25183 - DOI - PubMed
    1. Lin JJ, Cardarella S, Lydon CA, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol 2016;11:556-65. 10.1016/j.jtho.2015.12.103 - DOI - PMC - PubMed
    1. Pacheco JM, Gao D, Smith D, et al. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol 2019;14:691-700. 10.1016/j.jtho.2018.12.014 - DOI - PMC - PubMed
    1. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019. [Epub ahead of print]. - PMC - PubMed
    1. Gettinger S, Horn L, Jackman D, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol 2018;36:1675-84. 10.1200/JCO.2017.77.0412 - DOI - PubMed